Perioperative Challenges: Does Smoking Compromise High-Flow Nasal Oxygen Efficacy in Obese Men?

Not Applicable

Recruiting

• Conditions: Obese
• Interventions: Device: apnoeic

• Registration Number: NCT06562660
• Lead Sponsor: Henan Provincial People's Hospital

Brief Summary

There is a risk of airway-related incidents during anaesthesia associated with obesity. High-flow nasal oxygen is advocated for perioperative preoxygenation in obese patients to reduce airway adverse reactions. However, there have been no reports on whether smoking behaviors have an impact on obese men's Apnoeic oxygenation with high-flow nasal.This study compared the effects of smoking on the duration of safe apnoea times in obese males.

Detailed Description

All patients were were divided into two groups based on smoking status: smokers(S groups), and never smokers(NS groups). Those in the smoking group were current smokers, while those in the nonsmoking group had never smoked. Both groups of patients were induced with intravenous anesthesia and received 5 minutes of high flow nasal oxygen (60 L min) prior to induction.After induction of anaesthesia, the patients were apnoeic until peripheral oxygen saturation decreased to 95 %.

Study Timeline

• Study Start: 2024-05-01
• Study First Submitted: 2024-07-28
• Status Verified: 2024-08
• Study First Submitted QC: 2024-08-18
• Last Update Submitted: 2024-08-18
• Study First Posted: 2024-08-20
• Last Update Posted: 2024-08-20
• Primary Completion: 2025-03-01
• Study Completion: 2025-03-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Male
• Target Recruitment: 60

Inclusion Criteria

1. Participants ranged in age from 18 to 80 with BMI≥30 kg/m2.
2. Participants are male obese patients undergoing elective non-thoracic surgery

Exclusion Criteria :

1. patients were kept awake during the intubation due to cervical spine pathology.
2. Patients with unstable hemodynamics.
3. Patients with airway inflammatory diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary fibrosis and cystic fibrosis.
4. Patients with upper respiratory infection and nasal blockage.
5. Patients with Hypersensitivity to the drug.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Smoking group	apnoeic	In the Smoking group, the HFNC was performed after the patient lost spontaneous breathing until the end-tidal oxygen concentration reached 95 %. record the patient 's safe apnea time.

Primary Outcome Measures

Name	Time	Method
the safe apnoea times	5-minute	Investigators will record the time of oxygen saturation drop to 95 % during intubation.

Secondary Outcome Measures

Name	Time	Method
the Pao2 levels	5-minute	the Pao2 levels after 5-minute pre oxygenation with high flow nasal oxygen in two groups of patients.

Trial Locations

Locations (1)

Wanghuabing; 🇨🇳 Zhengzhou, China